Drugs / ADERBASIB
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00820560 | Jan 2005 → Jan 2009 | hematopoietic and lymphoid cell neoplasm | Incyte Corporation | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01254136 | Oct 2010 → Sep 2011 | breast cancer | Incyte Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT00864175 | Jul 2007 → Jun 2011 | breast cancer | Incyte Corporation | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADERBASIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103790 ↗ |
| Known as | INCB007839 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00864175 ↗ |
| Modality | Small molecule | — CHEMBL2103790 ↗ |
| Route | Oral | “multiple oral doses” NCT00820560 ↗ |